XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 30, 2022
Current assets:    
Cash and cash equivalents $ 540,597 $ 501,195
Short-term investments 772,536 807,273
Trade receivables, net 233,923 214,784
Inventory 29,908 33,299
Prepaid expenses and other current assets 60,654 62,211
Total current assets 1,637,618 1,618,762
Long-term investments 806,615 756,731
Property and equipment, net 116,212 110,624
Deferred tax assets, net 229,603 231,110
Goodwill 63,684 63,684
Right-of-use assets and other 289,627 290,578
Total assets 3,143,359 3,071,489
Current liabilities:    
Accounts payable 32,621 32,667
Accrued compensation and benefits 56,551 77,158
Accrued clinical trial liabilities 64,210 65,072
Rebates and fees due to customers 66,405 50,350
Accrued collaboration liabilities 18,324 20,188
Other current liabilities 89,486 78,924
Total current liabilities 327,597 324,359
Long-term portion of deferred revenue 6,299 6,582
Long-term portion of operating lease liabilities 186,948 190,170
Other long-term liabilities 67,379 61,951
Total liabilities 588,223 583,062
Commitments and contingencies (Note 10)
Stockholders' equity:    
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued 0 0
Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 324,985 and 323,951 at March 31, 2023, and December 31, 2022, respectively 325 324
Additional paid-in capital 2,558,297 2,536,849
Accumulated other comprehensive loss (9,289) (14,521)
Retained earnings (Accumulated deficit) 5,803 (34,225)
Total stockholders' equity 2,555,136 2,488,427
Total liabilities and stockholders' equity $ 3,143,359 $ 3,071,489